ClinicalTrials.gg
CompletedNCT00179647Updated Mar 16, 2010Results posted

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

A Phase 3 interventional study of lenalidomide and dexamethasone in Multiple Myeloma, sponsored by Celgene Corporation. Completed at 69 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-16.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,913
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
2nd of 249
1,913 · median 50
Started
2005
with 2 others
Phase 3
44 of 249
3 open now
Registered
13th of 249
by date
Lead sponsor
6 of 249
Celgene Corporation

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 44 in phase 3, and was the 13th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.

Read the detailed description

This was a multicenter, non-randomized, open-label, uncontrolled, single-arm treatment study of lenalidomide as monotherapy or in combination with dexamethasone in subjects with previously treated relapsed or refractory multiple myeloma, with measurable myeloma paraprotein in serum and/or urine. Subjects who met all of the eligibility criteria were enrolled into the study. Screening procedures took place within 28 days of first dose. Subjects who qualified for participation received oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days.

Subjects had the following options for dexamethasone treatment at the discretion of the treating physician:

Option A: No dexamethasone.

Option B: Oral pulse dexamethasone administered at a dose of 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle.

Option C: Oral pulse dexamethasone administered at a dose of 20 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle.

Option D: Oral dexamethasone administered at a dose of 40 mg weekly on Days 1, 8, 15, and 22 for each 28-day cycle for all cycles. Treatment was to be continued as tolerated until disease progression developed.

Doses of lenalidomide were allowed to be reduced first from 25 mg to 15 mg and then in 5-mg decrements due to lenalidomide toxicity. Subjects who could not tolerate a daily dose of 5 mg for 21 days every 28 days were discontinued from treatment. At the discretion of the investigator, doses of dexamethasone were modified due to dexamethasone toxicity. Dose reduction and discontinuation schemes for dexamethasone varied according to the treatment option administered.

Study visits occurred every 2 weeks for the first 3 cycles of therapy and then every 4 weeks after the third cycle until disease progression was documented, study drug was discontinued for another reason, or lenalidomide became commercially available for this indication.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • MM
  • Revlimid
  • CC5013
  • celgene
  • cc-5013
  • relapsed/refractory
  • lenalidomide
  • dexamethasone
  • Decadron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must understand and voluntarily sign an form.
  2. Must be > or = to 18 years of age at the time of signing the informed consent form.
  3. Must be able to adhere to the study visit schedule and other protocol requirements.
  4. Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has with progressive disease after treatment.
  5. Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied.
  6. Measurable levels of myeloma paraprotein in serum (>/=0.5 g/dL) or urine (>/=0.2 g excreted in a 24-hour collection sample).
  7. (ECOG) performance status score of 0, 1, or 2.
  8. Women of (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study medication.

Exclusion criteria

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form.
  2. Pregnant or lactating females.
  3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Any of the following laboratory abnormalities:

    1. (ANC) \<1,000 cells/mm3 (1.0 x 109/L)
    2. count \<75,000/mm3 (75 x 109/L) for subjects in whom \<50% of the bone marrow nucleated cells are plasma cells.
    3. Platelet count \<30,000/mm3 (30x109/L) for subjects in whom >/= 50% of bone marrow nucleated cells are plasma cells.
    4. Serum creatinine >2.5 mg/dL (221 mmol/L)
    5. Serum glutamic oxaloacetic transaminase (, aspartate transaminase [AST]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase [ALT]) >3.0 x (ULN)
    6. Serum total >2.0 mg/dL (34 mmol/L)
  5. Prior history of other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for >/= 1 year.
  6. Known to thalidomide or dexamethasone.
  7. Prior history of uncontrollable side effects to dexamethasone therapy.
  8. The development of a desquamating rash while taking thalidomide.
  9. Use of any standard/experimental anti-myeloma drug therapy within 28 days of the initiation of study drug treatment or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of the initiation of study drug treatment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,913 participants (actual)

Study arms

  • Other
    Lenalidomide 5-25 mg, w/wo dexamethasone

    single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone

    Drug: lenalidomide · Drug: dexamethasone

Interventions

  • Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone

    Also known as: Revlimid

  • Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.

    Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study.

    Time frame: Median time-on-study=18.3 weeks

  2. Overall Incidence of Adverse Events

    Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study.

    Time frame: Median time-on-study=18.3 weeks

07

Results

Posted Mar 3, 2010

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide
Started1913
Completed0
Not completed1913
Withdrew: Adverse event294
Withdrew: Lack of efficacy478
Withdrew: Withdrawal by subject83
Withdrew: Lost to follow-up4
Withdrew: Death94
Withdrew: Other960

Outcome measures

PrimaryIncidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.

Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study.

Time frame:
Median time-on-study=18.3 weeks

Results for this outcome have not been posted.

PrimaryOverall Incidence of Adverse Events

Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study.

Time frame:
Median time-on-study=18.3 weeks
Reported as:
Number · Participants
Overall Incidence of Adverse Events
ParticipantsLenalidomide
Overall Incidence of Adverse Events1877

Adverse events

Collected over Median time-on-study=18.3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—878/1,913 (45.9%)1,877/1,913 (98.1%)
Most frequent serious events
Showing 10 of 439
Most frequent serious events
EventLenalidomide
PNEUMONIAInfections and infestations168/1913
THROMBOCYTOPENIABlood and lymphatic system disorders79/1913
ANEMIABlood and lymphatic system disorders68/1913
PYREXIAGeneral disorders68/1913
FEBRILE NEUTROPENIABlood and lymphatic system disorders64/1913
DEEP VEIN THROMBOSISVascular disorders52/1913
MULTIPLE MYELOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)50/1913
NEUTROPENIABlood and lymphatic system disorders45/1913
DYSPNEARespiratory, thoracic and mediastinal disorders42/1913
DEHYDRATIONMetabolism and nutrition disorders41/1913
Most frequent other events
Showing 10 of 40
Most frequent other events
EventLenalidomide
FATIGUEGeneral disorders1072/1913
NEUTROPENIABlood and lymphatic system disorders618/1913
MUSCLE CRAMPMusculoskeletal and connective tissue disorders490/1913
CONSTIPATIONGastrointestinal disorders471/1913
DIARRHOEAGastrointestinal disorders430/1913
ANAEMIABlood and lymphatic system disorders423/1913
THROMBOCYTOPENIABlood and lymphatic system disorders408/1913
INSOMNIAPsychiatric disorders386/1913
NAUSEAGastrointestinal disorders362/1913
COUGHRespiratory, thoracic and mediastinal disorders301/1913

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lenalidomide
<=18 years0
Between 18 and 65 years1090
>=65 years823
Age Continuous
Age Continuous(years)Lenalidomide
Mean63.4 ± 10.31
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide
Female762
Male1151
Region of Enrollment
Region of Enrollment(participants)Lenalidomide
United States1183
Canada730
08

Study locations

69 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Alta Bates Cancer Center
    Berkeley, California 94704, United States
  • Scripps Cancer Center
    La Jolla, California 93037, United States
  • Cedar Sinai Medical CenterDept of Medicine
    Los Angeles, California 90048, United States
  • Kaiser Permanente Medical Group
    San Diego, California 32120, United States
  • Stanford Cancer Center
    Stanford, California 94305-5750, United States
  • Kaiser Permanente Medical Center
    Vallejo, California 94589, United States
  • University of ColoradoHealth Science Center
    Aurora, Colorado 80045-0510, United States
  • Rocky Mountain Cancer Center-Midtown
    Denver, Colorado 80218, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Hematology Oncology, PC
    Stamford, Connecticut 06902, United States
  • Delaware Clinical & Laboratory Physicians, PA
    Newark, Delaware 19713, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • University of Miami Medical School
    Miami, Florida 33136, United States
  • Gulf Coast Oncology
    St. Petersburg, Florida 33705, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 33612-9497, United States
  • The Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University Med CtrDivision of Hem/Onc
    Chicago, Illinois 60611-2927, United States
  • Rush Cancer Institute
    Chicago, Illinois 60612-3824, United States
  • Indiana Univ Cancer Center Bone Marrow Transplantation Program Indiana Cancer Research Institute
    Indianapolis, Indiana 46202-5254, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160-7233, United States
  • Wichita CCOP
    Wichita, Kansas 67214, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland Medical Center Greenbaum Cancer Ctr
    Baltimore, Maryland 21201-1595, United States
  • Center for Cancer And Blood Disorders
    Bethesda, Maryland 20817, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Jackson Oncology Associates
    Jackson, Mississippi 39202, United States
  • Siteman Cancer Center
    St. Louis, Missouri 63110, United States
  • Deaconess Billings Clinic
    Billings, Montana 59102, United States
  • Methodist Cancer Center
    Omaha, Nebraska 68114, United States
  • Nevada Cancer Center
    Las Vegas, Nevada 89109, United States
  • Dartmouth Hitchcock Medical Center-Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • The Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York Medical Center, MBCCOP
    Bronx, New York 10466, United States
  • SUNY Health Science Center - Brooklyn
    Brooklyn, New York 11203, United States
  • North Shore Hematology/Oncology Associates, PC
    East Setauket, New York 11733, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • NY Presbyterian Hospital/Weill Medical College-Cornell University
    New York, New York 10021, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Carolinas Hematology-Oncology Associates
    Charlotte, North Carolina 28203, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157-1023, United States
  • Dakota Cancer Institute
    Fargo, North Dakota 58108-6001, United States
  • Mid Ohio Oncology & Hematology, Inc.
    Columbus, Ohio 43215, United States
  • Kaiser Permanente Northwest RegionCenter for Health Research
    Portland, Oregon 97227, United States
  • University of Pennsylvania Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Western Pennsylvania Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Charleston Hematology/Oncology P.A.
    Charleston, South Carolina 29403, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • South Carolina Oncology Assoc
    Columbia, South Carolina 29210, United States
  • Avera Research Institute
    Sioux Falls, South Dakota 57105, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9016, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Intermountain Hematology/Oncology
    Salt Lake City, Utah 84124, United States
  • Medical College of Virginis, North Hospital
    Richmond, Virginia 23298, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Gunderson Clinic
    LaCrosse, Wisconsin 54601, United States
  • Marshfield Clinic
    Marshfield, Wisconsin 54449, United States
  • Oncology Alliance
    Milwaukee, Wisconsin 53215, United States
  • University of Calgary
    Calgary, Alberta 2N 4N1, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp
    Vancouver, British Columbia V5Z 4E3, Canada
  • Dalhousie University Queen Elizabeth II Health Services Centre
    Halifax, Nova Scotia B3H2Y9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5J 2M9, Canada
  • McGill University
    Montreal, Quebec H2W 1S6, Canada
09

References and documents

Publications

  • Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Bruyere H, Stewart DA, Bahlis NJ. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009 Jul 16;114(3):522-5. doi: 10.1182/blood-2008-12-193458. Epub 2009 Mar 30. PubMed 19332768 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Dec 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 16, 2005
Start
Sep 2005
Primary completionActual
Dec 2008
CompletionActual
Apr 2009
Results first posted
Mar 3, 2010
Last update
Mar 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00179647
Collaborators
Prologue Research International
First posted
Sep 16, 2005
Start date
Sep 2005
Primary completion
Dec 2008
Completion
Apr 2009
Results posted
Mar 3, 2010
Last update
Mar 16, 2010

Study contacts

Robert Knight, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion